q4
Sanofi sees FDA approval for diabetes drug
February 26, 2015Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4
US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …
Sanofi sales lifted by diabetes and rare diseases
February 6, 2015Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4
Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …
AstraZeneca looks for revenue boost via Actavis buy
February 6, 2015Sales and Marketing Actavis, AstraZeneca, Brilinta, Forxiga, diabetes, fourth quarter, q4
AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …
GSK blames respiratory woes as sales drop
February 5, 2015Sales and Marketing Advair, GSK, GlaxoSmithKline, HIV, ViiV, Witty, anoro ellipta, breo, lovaza, q4, sales
GlaxoSmithKline’s respiratory business has been flagged as the key factor in the firm’s fourth quarter financial misfortunes, as its total …
Gilead sales soar on back of hepatitis drugs
February 4, 2015Sales and Marketing Atripla, Gilead, efavirenz, emtricitabine, harvoni, lepidasvir, q4, sofosbuvir, sovaldi, tenofovi
The new blockbuster hepatitis C treatments Sovaldi and Harvoni more than doubled Gilead’s sales in the last quarter of 2014 …
Roche oncology sales shine but profits dip
January 29, 2015Sales and Marketing Kadcyla, Perjeta, Roche, avastin, fourth quarter, oncology, q4
Roche has posted a mixed bag of financial results complemented only by strong growth in its oncology and immunology divisions. …
Novartis sales below forecast in ‘transformative’ year
January 28, 2015Sales and Marketing Diovan, Exforge, Gleevec, Jimenez, Novartis, amlodipine, q4, valsartan
Novartis’ fourth quarter sales have faded slightly as growth in pharmaceuticals is beaten back by generic competition, and the firm …
Pfizer posts fourth-quarter revenue decline
January 28, 2015Sales and Marketing Eliquis, Lipitor, Lyrica (pregablin), Pfizer, Read, Xeljanz, apixaban, financials, pneumococcal vaccine Prevnar, q4, tofacitinib citrate
Pfizer posted a 3% decline in revenue in the last quarter of 2014, the company’s latest financial results show. The …
NICE recommends Bayer heart attack drug
January 26, 2015Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban
NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
Merck: ‘2014 revenues will be down’
February 7, 2014Sales and Marketing Frazier, Merck, Simponi, Singulair, isentress, q4, results
Merck is the latest pharma company to release figures suggesting 2013 was more of a struggle than it would like, …
AstraZeneca battling ‘headwinds’
February 7, 2014Sales and Marketing AstraZeneca, Soriot, farxiga, q4, results, xigduo
AstraZeneca is to shed another 550 jobs as its latest corporate restructure takes shape, bringing to 5,600 the number of …
Analysts ‘disappointed’ by Sanofi guidance
February 6, 2014Sales and Marketing Aubagio, Plavix, Sanofi, q4, sales
Sanofi has announced a mixed bag for its full year results as analysts have questioned why its forecasts for the …
GSK to make ‘fundamental changes’
February 6, 2014Sales and Marketing China, GSK, Tafinlar, Witty, q4, results
GlaxoSmithKline has pledged to make ‘fundamental changes’ to the manner in which it does business, looking at its interaction with …
Lilly to go ‘on offense’
January 31, 2014Sales and Marketing Alimta, Lechleiter, cymbalta, lilly, q4, zyprexa
The loss of patent on antidepressant Cymbalta in the US last December was largely responsible for Eli Lilly & Co’s …
